Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 15/20 | 1.00 |
| ▸ | RXRB | P28702 | 12/20 | 1.00 |
| ▸ | RXRG | P48443 | 8/20 | 1.00 |
| ▸ | RARB | P10826 | 8/20 | 1.00 |
| ▸ | RARG | P13631 | 7/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.68 |
| ▸ | RARA | P10276 | 5/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5681933 | 0.90 | RARB (0.82) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7720955 | 0.84 | RXRA (0.71) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL8460878 | 0.82 | RXRA (0.70) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7952347 | 0.82 | RARB (0.70) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7759680 | 0.82 | RXRA (0.69) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL846110 | 0.82 | RARB (0.81) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL29827631 | 0.82 | RARB (0.81) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL8674121 | 0.82 | RXRA (0.69) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL20278315 | 0.82 | RXRA (0.69) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL1073307 | 0.81 | RXRA (1.00) | RXRARXRBRXRGRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6391287-B1 | STORAGE STABLE COMPOSITIONS | L'OREAL (FR) | 2002-05-21 | — | — | US | claimed |
| EP-1019049-A1 | METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING NON-INSULIN DEPENDENT DIABETES MELLITUS (NIDDM) USING SPECIFIC RETINOID COMPOUNDS | Galderma Research & Development, S.N.C. (FR) | 2000-07-19 | — | — | EP | claimed |
| WO-1998042340-A9 | RETINOID RELATED MOLECULES FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS | — | 1999-03-04 | — | — | WO | claimed |
| WO-1998042340-A1 | RETINOID RELATED MOLECULES FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 1998-10-01 | — | — | WO | claimed |
| US-5766610-A | USEFUL FOR TREATMENT OF MAMMALIAN SKIN AND HAIR, RHEUMATISM, RESIPIRATORY SYSTEM DISORDER, CARDIOVASCULAR AND VISION DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-06-16 | — | — | US | claimed |
| EP-0679630-B1 | Bicyclic aromatic compounds, pharmaceutical and cosmetic compositions containing them and uses | CIRD GALDERMA (FR) | 1998-05-06 | — | — | EP | claimed |
| EP-0409729-B1 | Bi-aromatic thioesters, process for their preparation and their use in human or veterinary medicine and in cosmetics | CIRD GALDERMA (FR) | 1994-01-12 | — | — | EP | claimed |
| US-20070185055-A1 | Method for treating cachexia with retinoid ligands | JIANG GUANG LIANG | 2007-08-09 | — | — | US | disclosed |
| US-20070185055-A1 | Method for treating cachexia with retinoid ligands | JIANG GUANG LIANG | 2007-08-09 | — | — | US | disclosed |
| US-6391287-B1 | STORAGE STABLE COMPOSITIONS | L'OREAL (FR) | 2002-05-21 | — | — | US | disclosed |
| US-6162815-A | RXR-agonist polycyclic aromatic compounds, pharmaceutical/cosmetic compositions comprising said compound and uses thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-12-19 | — | — | US | disclosed |
| US-6156788-A | Polycyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-12-05 | — | — | US | disclosed |
| EP-1019049-A1 | METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING NON-INSULIN DEPENDENT DIABETES MELLITUS (NIDDM) USING SPECIFIC RETINOID COMPOUNDS | Galderma Research & Development, S.N.C. (FR) | 2000-07-19 | — | — | EP | disclosed |
| US-6015569-A | PYRIDINE OR PYRROLE DERIVATIVES OF POLYCYCLIC AROMATICS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-01-18 | — | — | US | disclosed |
| WO-1998042340-A9 | RETINOID RELATED MOLECULES FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS | — | 1999-03-04 | — | — | WO | disclosed |
| WO-1998042340-A1 | RETINOID RELATED MOLECULES FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 1998-10-01 | — | — | WO | disclosed |
| US-5766610-A | USEFUL FOR TREATMENT OF MAMMALIAN SKIN AND HAIR, RHEUMATISM, RESIPIRATORY SYSTEM DISORDER, CARDIOVASCULAR AND VISION DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185055-A1 | Method for treating cachexia with retinoid ligands | RXRA, RXRG, RXRB | RXRA 1/4885RXRB 3/4885RXRG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.